Published in Future Virol on August 01, 2012
The controversy over H5N1 transmissibility research: an opportunity to define a practical response to a global threat. Hum Vaccin Immunother (2013) 0.82
Influenza virus A/Anhui/1/2013 (H7N9) replicates efficiently in the upper and lower respiratory tracts of cynomolgus macaques. MBio (2014) 0.79
Mechanisms of action and efficacy of statins against influenza. Biomed Res Int (2014) 0.78
How to approach and treat viral infections in ICU patients. BMC Infect Dis (2014) 0.77
Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction. Viruses (2016) 0.75
Type I Interferon Counteracts Antiviral Effects of Statins in the Context of Gammaherpesvirus Infection. J Virol (2016) 0.75
In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature (2009) 14.59
Avian influenza A (H5N1) infection in humans. N Engl J Med (2005) 12.95
Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med (1989) 11.36
The pathology of influenza virus infections. Annu Rev Pathol (2008) 5.37
Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest (2007) 4.96
TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A (2009) 3.70
In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother (2002) 3.17
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis (2005) 2.72
Into the eye of the cytokine storm. Microbiol Mol Biol Rev (2012) 2.58
Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A (2008) 2.33
Host genetic background strongly influences the response to influenza a virus infections. PLoS One (2009) 2.28
Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol (2005) 2.13
A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc Natl Acad Sci U S A (2009) 2.04
Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother (2006) 2.00
Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis (2011) 1.91
Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies. J Infect Dis (2010) 1.82
Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A (2011) 1.73
Avian influenza: a new pandemic threat? Mayo Clin Proc (2004) 1.67
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis (2011) 1.66
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother (2003) 1.63
In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother (2001) 1.62
Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy (2007) 1.61
Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol (2003) 1.56
Influenza: epidemiology, clinical features, therapy, and prevention. Semin Respir Crit Care Med (2011) 1.55
Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Mol Pharmacol (2008) 1.48
Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest (2009) 1.44
Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis (2006) 1.44
Potential risks associated with the proposed widespread use of Tamiflu. Environ Health Perspect (2007) 1.39
Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis (2008) 1.35
Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One (2010) 1.30
Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother (2009) 1.27
Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respir Viruses (2009) 1.26
Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in mice. Antimicrob Agents Chemother (1992) 1.25
Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic. Clin Microbiol Rev (2012) 1.23
Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother (2007) 1.18
The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol (2007) 1.09
Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother (2001) 1.08
What happened in China during the 1918 influenza pandemic? Int J Infect Dis (2007) 1.08
Association between statins given in hospital and mortality in pneumonia patients. J Gen Intern Med (2011) 1.08
Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A (2004) 1.06
Combination chemotherapy for influenza. Viruses (2010) 1.02
Influenza ("Bird Flu"), inflammation and anti-inflammatory/analgesic drugs. Inflammopharmacology (2006) 1.02
A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine (2009) 1.00
Avian influenza: a review. Am J Health Syst Pharm (2007) 0.99
Experimental infection of H5N1 HPAI in BALB/c mice. Virol J (2007) 0.95
Seasonal and pandemic influenza preparedness: a global threat. J Infect Dis (2006) 0.93
Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication. Microbes Infect (2008) 0.93
Avian influenza viruses and their implication for human health. Clin Infect Dis (2004) 0.93
Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother (2001) 0.93
Treatment of severe cases of pandemic (H1N1) 2009 influenza: review of antivirals and adjuvant therapy. Recent Pat Antiinfect Drug Discov (2010) 0.92
Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respir Viruses (2010) 0.92
Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pract (2011) 0.90
Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology (2010) 0.90
Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza. Evid Based Complement Alternat Med (2009) 0.90
The effect of rosuvastatin in a murine model of influenza A infection. PLoS One (2012) 0.89
Statins, bugs and prophylaxis: intriguing possibilities. Crit Care (2006) 0.88
In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin. Chemotherapy (1996) 0.88
Fitness of neuraminidase inhibitor-resistant influenza A viruses. Curr Opin Virol (2011) 0.87
Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Res (2010) 0.86
Infectious disease. Old drugs losing effectiveness against flu; could statins fill gap? Science (2005) 0.86
The hemagglutinin protein of influenza A/Vietnam/1203/2004 (H5N1) contributes to hyperinduction of proinflammatory cytokines in human epithelial cells. Virology (2010) 0.86
Role of simvastatin and methyl-beta-cyclodextrin [corrected] on inhibition of poliovirus infection. Biochem Biophys Res Commun (2006) 0.85
Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur J Pharm Sci (2009) 0.84
Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1). Life Sci (2012) 0.84
Statins and influenza: can we move forward? J Infect Dis (2011) 0.81
Cheaper approaches to flu divide researchers. Nature (2007) 0.80
Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic. Med Hypotheses (2011) 0.79
Effects of simvastatin in patients with viral chronic hepatitis C. Hepatogastroenterology (2011) 0.77
Statins and outcomes in patients with pneumonia: appreciating bias and precision in study. BMJ (2006) 0.76
Flu season and the threat of a pandemic. Iowa Med (2007) 0.76
Conference urges greater effort to reduce human threat from avian influenza. BMJ (2007) 0.75
Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med (2010) 3.02
Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother (2006) 2.00
Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol (2006) 1.86
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother (2010) 1.84
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res (2009) 1.82
Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res (2013) 1.79
Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci U S A (2007) 1.71
Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother (2006) 1.49
Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother (2008) 1.40
Persistent West Nile virus associated with a neurological sequela in hamsters identified by motor unit number estimation. J Virol (2009) 1.38
Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res (2002) 1.35
Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One (2008) 1.32
Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother (2009) 1.31
Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother (2009) 1.27
Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents. Antimicrob Agents Chemother (2004) 1.25
Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS One (2009) 1.23
Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. Antiviral Res (2006) 1.23
Interferon alfacon-1 protects hamsters from lethal pichinde virus infection. Antimicrob Agents Chemother (2005) 1.20
Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol (2009) 1.15
Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral Res (2010) 1.13
Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother (2004) 1.10
Respiratory syncytial virus infections: recent prospects for control. Antiviral Res (2006) 1.10
Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res (2005) 1.08
Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. Antivir Chem Chemother (2004) 1.07
Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model. Antimicrob Agents Chemother (2011) 1.07
Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res (2009) 1.06
Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus. Antiviral Res (2003) 1.05
A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology (2009) 1.05
Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. J Virol Methods (2002) 1.05
New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion. J Virol (2013) 1.04
C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection. Antiviral Res (2008) 1.04
Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res (2009) 1.04
Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol J (2010) 1.02
Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antiviral Res (2008) 1.02
Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res (2012) 1.00
Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One (2012) 1.00
A porphyrin increases survival time of mice after intracerebral prion infection. Antimicrob Agents Chemother (2006) 0.99
Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res (2010) 0.98
Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine. Antiviral Res (2008) 0.97
Effect of exogenous interferon and an interferon inducer on western equine encephalitis virus disease in a hamster model. Virology (2006) 0.97
Nucleotide analogs as novel anti-hepatitis B virus agents. Curr Opin Pharmacol (2005) 0.94
Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochem Biophys Res Commun (2008) 0.93
Novel 3-sulphonamido-quinazolin-4(3H)-one derivatives: microwave-assisted synthesis and evaluation of antiviral activities against respiratory and biodefense viruses. Antivir Chem Chemother (2007) 0.92
Treatment of West Nile virus-infected mice with reactive immunoglobulin reduces fetal titers and increases dam survival. Antiviral Res (2005) 0.91
Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model. Antiviral Res (2010) 0.91
Neutralizing viruses in suspensions by copper oxide-based filters. Antimicrob Agents Chemother (2007) 0.90
Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs (2013) 0.89
Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. PLoS One (2010) 0.89
A recombinant, infectious human parainfluenza virus type 3 expressing the enhanced green fluorescent protein for use in high-throughput antiviral assays. Antiviral Res (2009) 0.88
Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice. J Gen Virol (2004) 0.88
Autonomic nervous dysfunction in hamsters infected with West Nile virus. PLoS One (2011) 0.88
Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J Med Chem (2011) 0.87
West Nile virus infection of the placenta. Virology (2006) 0.87
A self-processing ribozyme cassette: utility against human papillomavirus 11 E6/E7 mRNA and hepatitis B virus. Mol Ther (2004) 0.86
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J Med Chem (2003) 0.86
In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus. Arch Virol (2013) 0.86
Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice. Antiviral Res (2006) 0.85
Antiviral activities and phosphorylation of 5-halo-2'-deoxyuridines and N-methanocarbathymidine in cells infected with vaccinia virus. Antivir Chem Chemother (2008) 0.85
West Nile virus preferentially transports along motor neuron axons after sciatic nerve injection of hamsters. J Neurovirol (2009) 0.85
Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice. Vaccine (2007) 0.85
Enhanced antiscrapie effect using combination drug treatment. Antimicrob Agents Chemother (2006) 0.84
Immunoprophylaxis of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with recombinant Eimeria profilin-like antigen. Int Immunopharmacol (2008) 0.83
Use of plethysmography in assessing the efficacy of antivirals in a mouse model of pandemic influenza A virus. Antiviral Res (2011) 0.83
Broad-spectrum inhibitor of viruses in the Flaviviridae family. Antiviral Res (2005) 0.83
Treatment of spatial memory impairment in hamsters infected with West Nile virus using a humanized monoclonal antibody MGAWN1. Antiviral Res (2011) 0.83
In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Res (2011) 0.82
Punta Toro virus (Bunyaviridae, Phlebovirus) infection in mice: strain differences in pathogenesis and host interferon response. Virology (2009) 0.82
Evaluation of synthetic oligonucleotides as inhibitors of West Nile virus replication. Antiviral Res (2006) 0.82
Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin. Antiviral Res (2011) 0.81
Human parainfluenza virus type 3 (HPIV-3): construction and rescue of an infectious, recombinant virus expressing the enhanced green fluorescent protein (EGFP). Curr Protoc Microbiol (2010) 0.81
Fatal neurological respiratory insufficiency is common among viral encephalitides. J Infect Dis (2013) 0.80
Methods for evaluation of antiviral efficacy against influenza virus infections in animal models. Methods Mol Biol (2013) 0.79
Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs. Bioorg Med Chem Lett (2010) 0.79
Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice. Antivir Chem Chemother (2010) 0.79
in vitro inhibition of the measles virus by novel ring-expanded ('fat') nucleoside analogues containing the imidazo[4,5-e]diazepine ring system. Bioorg Med Chem Lett (2002) 0.78
Deletion of the D domain of the human parainfluenza virus type 3 (HPIV3) PD protein results in decreased viral RNA synthesis and beta interferon (IFN-β) expression. Virus Genes (2013) 0.77
Antiviral agents derived from novel 1-adamantyl singlet nitrenes. Antivir Chem Chemother (2012) 0.76
Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus. Chemotherapy (2008) 0.76
(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu). Bioorg Med Chem Lett (2010) 0.75
Autonomic deficit not the cause of death in West Nile virus neurological disease. Clin Auton Res (2013) 0.75
Antiviral activity of nucleoside analogues against SARS-coronavirus (SARS-coV). Antivir Chem Chemother (2006) 0.75